Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by MasterMedFacts LLC and RR Baliga MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC and RR Baliga MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

🌍 Obesity, Orals, Outcomes: Rewriting the GLP-1 Script

3:25
 
Share
 

Manage episode 507621416 series 2740117
Content provided by MasterMedFacts LLC and RR Baliga MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC and RR Baliga MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

💊 Orforglipron: A new era in obesity treatment?

In the ATTAIN-1 trial, this oral, nonpeptide GLP-1 receptor agonist delivered up to 11.2% weight loss over 72 weeks—with significant drops in waist circumference, triglycerides, and blood pressure 📉🌡️

🔥 Nearly 1 in 5 patients lost ≥20% body weight

💡 A promising alternative to injectable therapies

Accessible. Effective. Oral.

👉 A game-changer for global obesity care?

#Obesity #GLP1 #Orforglipron #WeightLoss #CardiometabolicHealth #NEJM #Innovation #ClinicalTrials #Endocrinology #PublicHealth #Pharmacotherapy

  continue reading

733 episodes

Artwork
iconShare
 
Manage episode 507621416 series 2740117
Content provided by MasterMedFacts LLC and RR Baliga MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC and RR Baliga MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

💊 Orforglipron: A new era in obesity treatment?

In the ATTAIN-1 trial, this oral, nonpeptide GLP-1 receptor agonist delivered up to 11.2% weight loss over 72 weeks—with significant drops in waist circumference, triglycerides, and blood pressure 📉🌡️

🔥 Nearly 1 in 5 patients lost ≥20% body weight

💡 A promising alternative to injectable therapies

Accessible. Effective. Oral.

👉 A game-changer for global obesity care?

#Obesity #GLP1 #Orforglipron #WeightLoss #CardiometabolicHealth #NEJM #Innovation #ClinicalTrials #Endocrinology #PublicHealth #Pharmacotherapy

  continue reading

733 episodes

所有剧集

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play